【摘要】：目的:觀察華蟾素膠囊聯(lián)合紫杉醇、順鉑治療中晚期宮頸癌的療效和安全性。方法:92例中晚期宮頸癌患者隨機分為對照組(46例)和觀察組(46例)。兩組患者均采用盆腔調(diào)強適形放射治療+近距離放射治療。在此基礎(chǔ)上,對照組患者給予紫杉醇注射液135 mg/m~2,d1+順鉑注射液75 mg/m~2,d1,21 d為1個周期,放療第1天開始化療,放療期間同步化療2個周期。觀察組患者在對照組治療的基礎(chǔ)上給予華蟾素膠囊0.5 g,口服,每日3次,于放療當天開始口服,直至放療結(jié)束。觀察兩組患者的臨床療效,治療前后血小板、功能狀態(tài)(KPS)評分、體質(zhì)量,疼痛患者的緩解情況及血小板異常患者的恢復情況,并記錄毒性反應(yīng)發(fā)生情況。結(jié)果:觀察組患者完全緩解率、血小板異�；颊叩幕謴驼Ｂ省⑻弁椿颊咧委�3周后的緩解率及總緩解率均顯著高于對照組,差異均有統(tǒng)計學意義(P0.05);兩組患者總有效率及疼痛患者治療4、5周后的緩解率比較,差異均無統(tǒng)計學意義(P0.05)。治療后,兩組患者血小板均顯著低于同組治療前,且觀察組顯著低于對照組;兩組患者KPS評分及觀察組患者的體質(zhì)量均顯著高于同組治療前,對照組患者的體質(zhì)量顯著低于同組治療前,且觀察組顯著高于對照組,差異均有統(tǒng)計學意義(P0.05)。觀察組患者Ⅲ～Ⅳ級白細胞下降、惡心嘔吐發(fā)生率,Ⅰ～Ⅱ級腹瀉發(fā)生率均顯著低于對照組,差異均有統(tǒng)計學意義(P0.05)。結(jié)論:在常規(guī)治療的基礎(chǔ)上,華蟾素膠囊聯(lián)合紫杉醇、順鉑治療中晚期宮頸癌的療效顯著,可改善患者血液高凝狀態(tài)及生存質(zhì)量,減輕疼痛,降低毒性反應(yīng)的發(fā)生。
[Abstract]:Objective: to observe the efficacy and safety of cinobufagin capsule combined with paclitaxel and cisplatin in the treatment of advanced cervical cancer. Methods: 92 patients with advanced cervical cancer were randomly divided into control group (46 cases) and observation group (46 cases). Both groups were treated with pelvic intensity modulation conformal radiotherapy. On this basis, the patients in the control group were given paclitaxel injection 135 mg/m~2,d1 DDP injection 75 mg/m~2,d1,21 d for one cycle. Chemotherapy began on the first day of radiotherapy and synchronous chemotherapy during radiotherapy for 2 cycles. On the basis of treatment in the control group, the patients in the observation group were given cinobufagin capsule 0.5 g, oral three times a day, which began on the day of radiotherapy until the end of radiotherapy. The clinical efficacy, platelet, functional (KPS) score, body mass, relief of pain patients and recovery of abnormal platelet were observed before and after treatment, and the occurrence of toxic reaction was recorded. Results: the complete remission rate of the patients in the observation group, the recovery rate of abnormal platelets, the remission rate and the total remission rate of the pain patients after 3 weeks treatment were significantly higher than those in the control group, the difference was statistically significant (P 0.05). There was no significant difference in the total effective rate and pain relief rate between the two groups after 5 weeks (P 0.05). After treatment, the platelets in both groups were significantly lower than those in the same group before treatment, and the platelet in the observation group was significantly lower than that in the control group. The KPS score of the two groups and the body mass of the observation group were significantly higher than those of the same group before treatment, the body mass of the control group was significantly lower than that of the same group before treatment, and the observation group was significantly higher than the control group, the difference was statistically significant (P 0.05). The incidence of grade III ~ IV leukopenia, nausea and vomiting and grade 鈪，

本文編號：2477669